trending Market Intelligence /marketintelligence/en/news-insights/trending/_WGZKeKZ6L_b45EKzPAUHA2 content esgSubNav
In This List

Blueprint Medicines closes common stock offering

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blueprint Medicines closes common stock offering

Blueprint Medicines Corp. closed its underwritten public offering of 5,750,000 common shares priced at $40 apiece with estimated net proceeds of about $215.6 million.

The underwriters for the offering fully exercised their option to buy additional common shares.

Goldman Sachs & Co., Morgan Stanley and Cowen and Co. acted as joint book-running managers for the offering, with Raymond James serving as co-manager.